Biotech

All Articles

Zephyrm finds Hong Kong IPO to cash phase 3 cell treatment tests

.Zephyrm Bioscience is gusting towards the Hong Kong stock exchange, filing (PDF) for an IPO to mone...

Frazier Lifestyle Sciences collects $630M for small, mid-cap biotechs

.Frazier Life Sciences has actually sourced an even more $630 million for its fund concentrated on t...

GigaGen amasses around $135M BARDA bucks to beat botox

.Antibody aficionado GigaGen, a subsidiary of Spanish biopharma Grifols, is actually increase its sp...

GPCR company Septerna files for IPO on stamina of preclinical records

.Septerna will figure out exactly how a biotech without "any kind of significant scientific data" fa...

Kurma closes to begin with $154M haul for most significant biotech fund yet

.International VC company Kurma Partners has introduced its latest biotech fund, along with 140 mill...

Prothena markets one officer while an additional places-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of notable leadership hirings, shootings and re...

Editas profit Vertex Cas9 licensing legal rights for $57M

.Versus the scenery of a Cas9 license struggle that rejects to die, Editas Medication is actually mo...

Ultragenyx tweaks gene therapy application to call up effectiveness

.A minority of clients taking Ultragenyx Pharmaceutical's Wilson illness gene treatment UX701 have g...

Biopharma unemployment fee maintains in Q3: Brutal Biotech review

.As summertime warmth turns to cool down winds, hopes that this year would bring common market comfo...

J &amp J drops stage 2 dengue prospect in most recent shift coming from vaccinations

.Johnson &amp Johnson's deprioritization of its own transmittable disease pipeline has claimed an ad...